Study to Evaluate the Safety and Efficacy of HI-BRITE Large Diameter Rigid Gas Permeable Contact Lens

Overview

Study to evaluate the safety and efficacy of HI-BRITE large diameter rigid gas permeable contact lens (hexafocon b) test when worn on a daily wear basis in the correction of myopia/hyperopia/astigmatism/presbyopia/ and irregular cornea.

Full Title of Study: “Study to Evaluate the Safety and Efficacy of HI-BRITE Large Diameter Rigid Gas Permeable Contact Lens (Hexafocon b) Test When Worn on a Daily Wear Basis in the Correction of Myopia/Hyperopia/Astigmatism/Presbyopia/ and Irregular Cornea.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 2017

Detailed Description

Subjects who meet all eligible requirements for entry into the study will be instructed to insert the Hi-Brite Large Diameter Rigid Gas Permeable contact lens in daily wear basis for clinical evaluation purposes. Treatment period: 6 months

Interventions

  • Device: HI-BRITE Large Diameter Rigid Gas Permeable Contact Lens
    • Approximately At least one hundred and forty (140) subjects (280 eyes) will be enrolled in this study at approximately two (2) clinical sites in Taiwan. All subjects will be fitted for and dispensed study lenses by each Investigator.

Arms, Groups and Cohorts

  • Experimental: Scleral lenses
    • Subjects who meet all eligible requirements for entry into the study will be instructed to insert the Hi-Brite Large Diameter Rigid Gas Permeable contact lens in daily wear basis for clinical evaluation purposes.

Clinical Trial Outcome Measures

Primary Measures

  • The success rate of the vision with correction
    • Time Frame: Wearing the contact lens for 6 months
    • Ametropic group: Subjects wear their lens for at least 6 hours/day and 5 days/ week after visit 9, Distance Lens VA is not less than 20/25 and 90% subjects’ VA decreased less than 2 lines with Snellen’s chart at the last visit. Irregular Cornea Group: Subjects wear their lens for at least 6 hours/day and 5 days/ week after visit 9, Distance Lens VA is not less than 20/40 and 80% subjects’ VA decreased less than 2 lines with Snellen’s chart at the last visit.

Secondary Measures

  • The effectiveness of each visit
    • Time Frame: wearing the contact lens for 6 months
    • Ametropic group: To assess each subject for the lens satisfied / problem and assess each time of the vision with correction; the ratio of ametropic correcting vision of 20/25 subjects. Irregular Cornea Group: To assess each subject for the lens satisfied / problem and assess each time of the vision with correction; the ratio of the irregular cornea corrected visual acuity of 20/40 subjects.
  • The rate of Treatment-Emergent Adverse Events to assess the safety of each visit
    • Time Frame: wearing the contact lens for 6 months
    • To assess the rate of adverse reactions, the proportion of corneal ulcers, the proportion of continuous stroma edema, significant proportion of corneal staining of luciferase, the proportion of corneal infections, the proportion of persistent inflammation of the eyelids, and the proportion of other eye discomfort.

Participating in This Clinical Trial

Inclusion Criteria

  • Ametropic or irregular cornea subjects who need to wear spectacle lens or contact lens in their daily life. – Is of age at least 20 years old and no older than 65 years old capacity to volunteer. – Has read and signed the Informed Consent Form or waiver. (4) Has myopia or hyperopia -20.00D~+20.00D, astigmatism -0.25~-4.00D, or presbyopia +1.00D~+3.50D. – Irregular cornea subjects include keratoconus, high astigmatism (>-4.00D) or post-refractive surgery patients. – No active ocular disease, infection or any disorder of eyelids and conjunctiva. – Has reasonable expectation of improvement in visual acuity with the test lenses. – Is willing and able to follow subject instructions and meet the protocol -specified visit schedule. (If subjects missed any visit, they must be discontinued from the study.) (9) Agrees to wear the test lenses at a daily wear basis. (10) Willing to adapt wearing GP contact lens. Exclusion criteria:

The subject is ineligible for entry into the study if the subject

  • Has any systemic disease affecting ocular health. – Is using any systemic or topical medications that will, in the Investigator's opinion. Affect ocular physiology or lens performance within one (1) week before entering this study. – Has an active ocular disease or has ever used systemic steroid or any other medicine that may affect significant on vision or healing. – Has any Grade 2 or greater finding listed in the Quantification of Slit Lamp Observations Form. Subjects with corneal infiltrates, however, of ANY GRADE, are not eligible. – Has any "Present" finding listed in the Quantification of Slit Lamp Observations that, in the Investigators' judgment, interferes with contact lens wear. – Has any scar or neovascularization within the central 4mm of the cornea. Subjects with minor peripheral corneal scarring that, in the Investigator's judgment, does not interfere with contact lens wear are eligible for this study. – Severe dry eye (Schirmer Test<5mm/5min) – Corneal keratitis – Is aphakic – Had undertaken the following surgery: Retina, Glaucoma, Cataract surgery. – Is amblyopic, BSCVA can't achieve (include) 20/40(0.5) when wear trial lenses. – Allergy to contact lens solution. – ls participating in any other clinical research study. – Pregnancy or Breast-feeding.

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Taipei Medical University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Tsung-Jen Wang, Dr., Principal Investigator, Taipei Medical University Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.